Skip to main content
Evidence Snapshot

Autotaxin

CHEMBL3691 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3691
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Autotaxin as ChEMBL target CHEMBL3691, mapped to UniProt Q13822. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Autotaxin
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3691
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13822
Autotaxin
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Autotaxin matters

As of 2026-09-13

Autotaxin is reviewed as Autotaxin (UniProt Q13822); Autotaxin shows late clinical disease relevance led by idiopathic pulmonary fibrosis. 2 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 3479 compounds, and 292 assays, with lead potency reaching pChEMBL 11.0.

Disease context
idiopathic pulmonary fibrosis

Autotaxin shows late clinical disease relevance led by idiopathic pulmonary fibrosis. 2 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include ZIRITAXESTAT.

Start review with idiopathic pulmonary fibrosis because it currently carries late clinical support. Linked drugs include ZIRITAXESTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 3479 compounds, and 292 assays for this target. The dominant activity type is IC50. CHEMBL3828074 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL3828074 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Autotaxin matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13822, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why idiopathic pulmonary fibrosis is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3479
Total Compounds
292
Total Assays
5
Approved Drugs
IC50: 3758.0, KI: 134.0, EC50: 10.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3828074
 11.0 IC50 Clinical
No preferred name
CHEMBL5183599
 9.4 IC50 —
No preferred name
CHEMBL4640012
 9.4 IC50 —
No preferred name
CHEMBL5766179
 9.0 IC50 —
No preferred name
CHEMBL5759407
 9.0 IC50 —

Approved Drugs

Structure Compound First Approval
DRONABINOL
CHEMBL465
 1985
EVANS BLUE
CHEMBL1200712
 1982
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3691